Researchers

NISHIDA Naoshi

NISHIDA Naoshi
Specially Appointed Professor
Faculty Department of Medicine / Graduate School of Medical Sciences
Researchmap https://researchmap.jp/naoshinishida

Education and Career

Education

  • - 1985 , Osaka Medical College, Faculty of Medicine,
  • - 1993 , Kyoto University, Graduate School of Medicine,

Academic & Professional Experience

  • Apr. 2026 - Today , Kindai University Faculty of Medicine Department of Medicine Professor
  • Apr. 2021 - Mar. 2026 , Kindai University Faculty of Medicine Professor
  • Aug. 2011 - Mar. 2021 , Fuculty of Medicine Kindai University Department of Gastroenterology and Hepatology Associate Professor
  • Aug. 2006 - Jul. 2011 , Kyoto University Graduate School of Medicine Department of Gastroenterology and Hepatology Assistant Professor/Lecture
  • Feb. 2004 - Jul. 2006 , Baylor University Medical Center Division of Gastroenterology Reserach Associate
  • Apr. 1997 - Jan. 2004 , Kyoto University Graduate School of Medicine Department of Medicine and Clinical Science Assistant Professor
  • May. 1996 - Apr. 1997 , Research Institute for Production Development Researcher

Research Activities

Research Areas

  • Informatics, Biological, health, and medical informatics
  • Life sciences, Genomics
  • Life sciences, Gastroenterology

Research Interests

data base, artificial Intelligence, Molecular Biology, Hepatology, Gastroenterology, Epigenetics, chromosome, tumor suppressor gene, Hepatocellular carcinoma

Published Papers

  1. Curative treatment is feasible for recurrent hepatocellular carcinoma regardless of recurrence pattern after hepatitis C virus eradication with interferon-free direct-acting antiviral therapy.
    Satoru Hagiwara; Takuya Matsubara; Naoya Omaru; Natsuki Okai; Yoriaki Komeda; Kazuomi Ueshima; Yasunori Minami; Masahiro Takita; Masahiro Morita; Hirokazu Chishina; Akihiro Yoshida; Naoshi Nishida; Masatoshi Kudo
    BMC gastroenterology  22, Jun. 2026  , Refereed
  2. A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab Plus bevacizumab in hepatocellular caarcinoma.
    Pasquale Lombardi; Erik Ramon-Gil; Rabial Q Raja; Leonardo Brunetti; Giulia Francesca Manfredi; Zhongguo Zhou; George Merces; Sarah Cappuyns; Claudia Angela Maria Fulgenzi; Antonio D'Alessio; Aria Torkpour; Ciro Celsa; Bernardo Stefanini; Hannah Yang; Fionnuala Crowley; Thomas U Marron; Anwaar Saeed; Matthias Pinter; Bernhard Scheiner; Yi-Hsiang Huang; Pei-Chang Lee; Naoshi Nishida; Ryan Po-Ting Lin; Andrea Dalbeni; Caterina Vivaldi; Gianluca Masi; Natascha Rohlen; Johann von Felden; Ahmed Kaseb; Peter R Galle; Masatoshi Kudo; Wei-Fan Hsu; Lorenza Rimassa; Alessandro Parisi; Robin Kate Kelley; Hidenori Toyoda; Mario Pirisi; Falah Jabar; Mehrdad Rakaee; Giuseppe Cabibbo; Calogero Cammà; Fabio Piscaglia; Sohyun Hwang; Dong Jun Shin; Michael Li; Jeroen Dekervel; Nadia Guerra; Tim Meyer; Helen L Reeves; Bertram Bengsch; Gennaro Daniele; Derek A Mann; Hong Jae Chon; Jack Leslie; David J Pinato
    Journal of Hepatology  15, Jun. 2026  , Refereed
  3. Regardless of the Pattern of Recurrence, Recurrent Hepatocellular Carcinoma Treated with Interferon-Free Direct-Acting Antiviral Therapy can be Selected and Administered as a Curative Treatment
    Satoru Hagiwara; Takuya Matsubara; Naoya Omaru; Natsuki Okai; Yoriaki Komeda; Kazuomi Ueshima; Yasunori Minami; Masahiro Takita; Masahiro Morita; Hirokazu Chishina; Akihiro Yoshida; Naoshi Nishida; Masatoshi Kudo
    5, Jun. 2026 

MORE

Books etc

  1. Clinical Practice Guidelines for Hepatocellular Carcinoma , Naoshi Nishida , Tumor immune microenviroment of hepatocellular carcinoma and It's clinical implicaiton , 医学書院 , Apr. 2025
  2. Clinical Practice Guidelines for Hepatocellular Carcinoma , Naoshi Nishida , Clinical Significance of genomic and epigenetic alterations in hepatocellular carcinoma , 医学書院 , Apr. 2025
  3. Immunotherapy in Hepatocellular Carcinoma , Naoshi Nishida; Masatoshi Kudo , MDPI Books , Apr. 2023

MORE

Conference Activities & Talks

  1. Longitudinal Changes in Liver Function During Systemic Therapy for Hepatocellular Carcinoma: Impact of Anti-VEGF Agetns , Masahiro Morita; Naoshi Nishida; Takuya Matsubara; Naoya Omaru; Natsuki Okai; Hirokazu Chishina; Tomoko Aoki; Masahiro Takita; Satoru Hagiwara; Yasunori Minami; Kazuomi Ueshima; Masatoshi Kudo , The 62nd Annual Meeting of Japan Liver Cancer Association , 18, Jul. 2026
  2. Stratification of Tumor Immune Microenvironment and Genomic Alterations in Intrahepatic Cholangiocarcinoma , Naoshi Nishida; Tomoko Aoki; Yutaka Kurebayashi; Takuya Matsubara; Naoya Omaru; Natsuki Okai; Masahiro Morita; Hirokazu Chishina; Masahiro Takita; Satoru Hagiwara; Yasunori Minami; Kazuomi Ueshima; Masatoshi Kudo , The 62nd Annual Meeting of Japan Liver Cancer Association, Workshop 3: New Trend in Intrahepatic Cholangiocellular Carcinoma , 18, Jul. 2026
  3. Redefining the Tumor Immune Microenvironment in FDG-PET–Positive Hepat ocellular Carcinoma: The Role of the Hypoxia–Lactate Axis and Fibrosis -Driven Remodeling , Tomoko Aoki; Shinji Ito; Naoshi Nishida; Masatoshi Kudo , The 62nd Annual Meeting of Japan Liver Cancer Association, Symposium 3 , 17, Jul. 2026

MORE

MISC

  1. AI超音波診断装置の到達点と今後 先進技術による診断支援とは如何なるものか 腹部超音波領域におけるAI開発の現況と肝腫瘤診断支援への応用 , 西田 直生志 , 新医療 , 53 , 5 , 86 , 90 , May. 2026
  2. 【肝・胆・膵がんの薬物療法2026 update】肝細胞がん Advanced stage肝細胞がんに対するfirst-lineの全身薬物療法をどう選ぶ? , 青木 智子; 上嶋 一臣; 西田 直生志; 工藤 正俊 , 腫瘍内科 , 37 , 2 , 120 , 130 , Feb. 2026
  3. 【肝内胆管癌の再考-small ductとlarge duct型分類のインパクト-】病態と腫瘍発生 肝内胆管癌のゲノム,エピゲノム,腫瘍免疫 , 西田 直生志 , 肝胆膵 , 91 , 5 , 583 , 590 , Nov. 2025

MORE

Awards & Honors

  1. Apr. 2026, The Japanese Society of Gastroenterology, Journal of Gastroenterology High Citation Award
  2. Dec. 2025, Terumo Life Science Foundation, FY 2025 Medical Contribution Activity Subsidy
  3. May. 2025, AME Publishing Company, Outstanding Authors

MORE

Research Grants & Projects

  1. Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research, Aberrant Epigenomic Regulation Underlying Resistance to Combination Immunotherapy in Intrahepatic Cholangiocarcinoma , Kindai University
  2. Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research, Metabolic Reprogramming via Glycolysis Enhancement: A Novel Approach to Overcoming Treatment Resistance in Hepatocellular Carcinoma through Immune Microenvironment Modulation , The University of Tokyo
  3. Terumo Life Science Foundation, FY 2025 Medical Contribution Activity Subsidy, Multimodal AI for Early Ultrasound Detection of Liver Cancer

MORE